DIRS.INFO The most relevant business & tech news

☆ Lupin Global CFO: Medicine business benefitting from supply chain diversification
▼ + stars: | 2024-11-08 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLupin Global CFO: Medicine business benefitting from supply chain diversificationRamesh Swaminathan, Global CFO of Lupin discusses the impact of Trump's win on the Indian pharmaceutical sector. Growing demand for affordable medicines, and diversification from China are key factors benefitting his company. He also talks about R&D and productivity as drivers to further increase margins.

Persons: Ramesh Swaminathan, Lupin Organizations: Medicine Locations: China

☆ UTI International: We see a great future for Indian pharma
▼ + stars: | 2024-10-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUTI International: We see a great future for Indian pharmaPraveen Jagwani, CEO of UTI International, discusses the rise of Indian pharma in the wake of the U.S. Biosecure Act dampening competition from China.

Organizations: Indian pharma, Jagwani, UTI Locations: China

☆ The U.S. and India remain our most important markets: Indian pharmaceutical company Lupin
▼ + stars: | 2024-05-07 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe U.S. and India remain our most important markets: Indian pharmaceutical company LupinRamesh Swaminathan, global CFO and executive director of Lupin, discusses the company's earnings report.

Persons: Lupin Ramesh Swaminathan, Lupin Locations: India

☆ We're in for a period of secular growth, says Indian pharmaceutical firm
▼ + stars: | 2024-02-08 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe're in for a period of secular growth, says Indian pharmaceutical firmRamesh Swaminathan of Lupin discusses its product pipeline and U.S. sales forecast.

Persons: Ramesh Swaminathan, Lupin

Poli Devi, whose 11-month-old daughter Janvi was among the children who died due to kidney injury after consuming contaminated cough syrup, holds a photo of her at their house in Ramnagar on the outskirts of Jammu, India, March 28, 2023. REUTERS/Anushree Fadnavis/File Photo Acquire Licensing RightsNEW DELHI, Oct 4 (Reuters) - India's drug regulator has found that a cough syrup and an anti-allergy syrup made by Norris Medicines (NORI.BO) are toxic, according to a government report, months after Indian-made cough syrups were linked to 141 children's deaths worldwide. Koshia said Norris used to export the cough syrup, but did not say where. "We are aware of the CDSCO report and have communicated with that agency to ascertain where the products... have been exported," said a WHO spokeswoman. The CDSCO also found three batches of COLD OUT syrup made by Fourrts (India) Laboratories contaminated with DEG and EG.

Persons: Poli Devi, Janvi, Anushree, Koshia, Norris's, Norris, Vimal Shah, S.V, Veeramani, Adani Wilmar, Krishna N, Jennifer Rigby, Andrew Heavens, Nick Macfie, William Maclean Organizations: REUTERS, Norris Medicines, Central Drugs Standard Control, EG, Drug Control Administration, Reuters, World Health Organization, WHO, Laboratories, World Health Organisation, Fourrts, Pharmaceuticals Export, of India, Thomson Locations: Ramnagar, Jammu, India, DELHI, Gambia, Uzbekistan, Cameroon, Gujarat, Fourrts, Iraq, pharmexcil

☆ India-Canada relations: how could trade be affected as tensions rise?
▼ + stars: | 2023-09-19 | by ( Manoj Kumar | ) www.reuters.com time to read: +5 min

On Tuesday, New Delhi dismissed the allegations as "absurd", and asked Canada instead to crack down on anti-India elements operating in its territory. Here is what is at stake for both countries:HOW ARE TRADE TALKS AFFECTED? Steady growth has seen goods trade rising to $8 billion in 2022, with Indian exports to Canada touching $4 billion and imports from Canada also worth $4 billion. Pharmaceutical products, worth about $418 million, made up the bulk of Indian exports last year, followed by iron and steel products worth about $328 million and machinery, nuclear reactors and boilers worth about $287 million. India's growing demand for imported lentils has benefited Canadian farmers, while Indian pharmaceutical and software companies have expanded their presence in the Canadian market.

Persons: Hardeep Singh Nijjar, Nanak, Chris Helgren, Justin Trudeau, Canpotex, Manoj Kumar, Arpan Varghese, Jaiveer, Clarence Fernandez, Anil D'Silva Organizations: REUTERS, Trading Economics, UN, Canpotex, Pharmaceutical, Caisse, Ontario Teachers, Bombardier, SNC Lavalin, TCS, Infosys, Wipro, Canadian Bureau of International Education, Thomson Locations: Surrey, British Columbia, Canada, DELHI, India, New Delhi, India's, Punjab, Bengaluru

☆ India-Canada row: What is at stake?
▼ + stars: | 2023-09-19 | by ( Manoj Kumar | ) www.reuters.com time to read: +3 min

Here is what is at stake for both countries:HOW ARE TRADE TALKS AFFECTED? Steady growth has seen goods trade rising to $8 billion in 2022, with Indian exports to Canada touching $4 billion and imports from Canada also worth $4 billion. India's growing demand for imported lentils has benefited Canadian farmers, while Indian pharmaceutical and software companies have expanded their presence in the Canadian market. WHAT IS THE ROLE OF INDIAN STUDENTS IN CANADA? Since 2018, India has been the largest source country for international students in Canada.

Persons: Justin Trudeau, Manoj Kumar, Clarence Fernandez Organizations: Bombardier, SNC Lavalin, TCS, Infosys, Wipro, Canadian Bureau of International Education, Thomson Locations: DELHI, India, Canada, New Delhi, India's, Punjab

☆ There's been secular growth across all our markets, says Indian pharmaceutical company
▼ + stars: | 2023-08-04 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThere's been secular growth across all our markets, says Indian pharmaceutical companyRamesh Swaminathan of Lupin says there was growth in markets such as the EU and Australia.

Persons: Ramesh Swaminathan, Lupin Organizations: EU Locations: Australia

Two other cough syrups made in India killed 19 children in Uzbekistan around December, according to the Uzbekistan government. India's overall pharma exports in the April-June quarter rose 5% to $6.58 billion. COUNTRY VISITSPharmexcil delegations have visited countries including Nigeria, Egypt and Russia in recent months to allay any concerns about Indian drugs, he said. Apart from Gambia, no other country has asked for additional tests for Indian drugs since the deaths, he said. Manufacturing a drug in Europe or the United States costs more than 30% than in India, giving India a big advantage, he said.

Persons: syrups, Udaya Bhaskar, Bhaskar, drugmakers, Krishna N, Alison Williams Organizations: Reuters, World Health Organization, WHO, pharma, Pharmaceuticals Export, of India, India's pharma, Marion Biotech, Thomson Locations: DELHI, Gambia, India, Uzbekistan, United States, China, U.S, Nigeria, Egypt, Russia, South Africa, Brazil, Europe

The company, Marion Biotech, bought the ingredient — propylene glycol (PG) — from trader Maya Chemtech India, as reported by Reuters. "Marion bought commercial-grade propylene glycol," said a second source, an investigator, who declined to be named while the inquiry is ongoing. International standards allow only trace amounts of EG and DEG in pharmaceutical-grade propylene glycol. The toxins were found in cough syrups exported to Gambia by the other Indian company, Maiden Pharmaceuticals. India made it mandatory for companies to have their cough syrups tested before export from June.

Persons: Marion, Deepak Sharma, Max, Vijay Kumar, Tuhin Bhattacharya, Mool Singh, Atul Rawat, Jaya Jain, Sachin Jain, Rohan Gupta, syrups, Maiden, Saurabh Sharma, Krishna, Jennifer Rigby, Olzhas, Sara Ledwith, Michele Gershberg, Deepa Babington Organizations: Reuters, Marion Biotech, Indian, EG, World Health Organization, Authorities, . Police, Marion, Court, Maya, Maiden Pharmaceuticals, WHO, Thomson Locations: DELHI, Uzbekistan, India, Delhi, Marion, Uttar Pradesh, Allahabad, Gambia, Indonesia, London, Almaty

Health Minister Mansukh Mandaviya and federal and state regulators attended the session in February, according to a statement from the health ministry that did not mention cough syrups. A source with knowledge of the matter said the policy change could mean increased oversight of India's $41 billion pharmaceutical industry, which is the world's largest supplier of generic medicines. Increased testing of cough syrups as well as of raw materials for drugs in general is one of the steps being considered, said the source. India has acted against a second Indian company whose cough syrups were linked to the deaths of 19 kids in Uzbekistan, including the arrest of three of its employees. Indian health officials have expressed concern that the incidents of contaminated syrups will harm its pharmaceutical industry.

☆ Can Africa Get Close to Vaccine Independence? Here’s What It Will Take.
▼ + stars: | 2023-04-25 | by ( Stephanie Nolen | ) www.nytimes.com time to read: +2 min

The expense of putting it all in place means that vaccines made in Africa are going to cost significantly more than those from the Indian pharmaceutical industry, which is the major supplier of routine vaccines used in Africa. But the Covid vaccine rollout made clear that despite the low price of Indian-made vaccines, African leaders cannot afford to rely on them. In March 2021, when millions of Serum-made doses of the AstraZeneca vaccine were bound for Africa, the Indian government imposed an export ban and rerouted those vaccines to its own population. The Africa Centers for Disease Control and Prevention says the continent’s existing vaccine market is worth an estimated $1.3 billion and is expected to grow to about $2.4 billion by 2030. Gavi buys half the vaccines used in Africa today.

☆ India, Russia in talks on free trade deal
▼ + stars: | 2023-04-17 | by ( ) www.reuters.com time to read: +2 min

[1/2] Indian Foreign Minister Subrahmanyam Jaishankar attends a news conference following talks with his Russian counterpart Sergei Lavrov in Moscow, Russia, November 8, 2022. Maxim Shipenkov/Pool via REUTERSNEW DELHI, April 17 (Reuters) - India and Russia are discussing a free trade agreement, ministers said on Monday, a move that would further deepen bilateral commercial ties that have flourished since war broke out in Ukraine. Russia, a traditional defence equipment supplier, also displaced Iraq last month to become India's top supplier of crude oil. Moscow was looking to increase machinery imports from India to improve the trade balance, Manturov said. India too aims to narrow its growing trade deficit with Russia, which has been India's largest supplier of military equipment for decades and is the fourth-biggest market for Indian pharmaceuticals.

☆ Inside the Online Market for Overseas Abortion Pills
▼ + stars: | 2023-04-13 | by ( Allison Mccann | ) www.nytimes.com time to read: +17 min

A selection of abortion pill kits available online from overseas sellers. A chart of the estimated number of abortion pills provided outside the U.S. health care system from July through December 2022. For most patients, the cost of the service remains the most important factor in deciding where to get pills online. A chart showing the minimum, average and maximum cost of abortion pills from overseas providers: Aid Access, Las Libres and for-profit online sellers. A chart showing the minimum, average and maximum delivery speeds of abortion pills from overseas providers: Aid Access, Las Libres and for-profit online sellers.

☆ India shared a list of products with Moscow for access to Russian market - minister
▼ + stars: | 2022-12-05 | by ( ) www.reuters.com time to read: +2 min

Russia has been India's largest supplier of military equipment for decades and it is the fourth-biggest market for Indian pharmaceuticals. "We have given Russians a set of products which we believe we are very competitive in and which we feel should be getting access to the Russian market," Jaishankar told reporters in a briefing with his German counterpart Annalena Baerbock, who is on a visit to India. I think a large part of it would be determined by the market," Jaishankar added. During a visit to Moscow in November, Jaishankar said India needed to boost exports to Russia to balance bilateral trade that is now tilted towards Russia. Reporting by Shivam Patel in New Delhi; Editing by Alison Williams and Peter GraffOur Standards: The Thomson Reuters Trust Principles.

[1/3] Russian Foreign Minister Sergei Lavrov and his Indian counterpart Subrahmanyam Jaishankar attend a news conference following their talks in Moscow, Russia, November 8, 2022. India is keen to boost trade in this way, said the source, as it tries to narrow a ballooning trade deficit with Russia. During the Moscow visit, Jaishankar said India needed to boost exports to Russia to balance bilateral trade that is now tilted towards Russia. The list of items from Russia, which runs to nearly 14 pages, includes car engine parts like pistons, oil pumps and ignition coils. India is hoping to boost its exports to nearly $10 billion over coming months with Russia's list of requests, according to the government source.

☆ India's Modi calls for diplomacy to end Russia-Ukraine conflict
▼ + stars: | 2022-11-15 | by ( ) www.reuters.com time to read: +2 min

ADITYA PRADANA PUTRA/G20 Media Center/Handout via REUTERSNov 15 (Reuters) - India Prime Minister Narendra Modi on Tuesday urged a return to diplomacy to end the Russia-Ukraine war, reiterating the South Asian nation's call for peace in the ongoing conflict. India has not condemned Moscow's invasion of Ukraine, but Modi told Russian President Vladimir Putin in September that "today's era is not an era of war". "I have repeatedly said that we have to find a way to return to the path of ceasefire and diplomacy in Ukraine," Modi said in his opening remarks at the Group of 20 (G20) summit in Bali, Indonesia. There should be no restrictions on energy supplies and stability in the energy market should be ensured, Modi said. "India's energy security is also important for global growth," said Modi, according to a statement released by the Indian foreign ministry.

☆ Pfizer's India arm posts profit jump on lower costs, price hikes
▼ + stars: | 2022-11-11 | by ( ) www.reuters.com time to read: +1 min

BENGALURU, Nov 11 - Pfizer Ltd (PFIZ.NS), the Indian arm of U.S. pharma giant Pfizer Inc (PFE.N), reported a rise in second-quarter profit on Friday, boosted by price hikes and lower input costs. Profit before tax and exceptional item rose to 2.26 billion Indian rupees ($27.97 million) in the three months ended Sept. 30, from 1.75 billion rupees in the year-ago period. The company booked a one-time gain of 1.89 billion rupees on the sale its off-patent and generic medicines business, Upjohn. Pfizer's revenue from operations rose 0.3% to 6.38 billion rupees. Earlier in the day, peer Zydus Lifesciences (ZYDU.NS) reported an 82.6% slump in second-quarter profit, hit by rising expenses.

His trip comes as U.S. Treasury Secretary Janet Yellen visits New Delhi this week to hold talks with Indian officials, including possibly on capping Russian oil prices. India has become Russia's largest oil customer after China, as its refiners snap up discounted cargoes shunned by Western buyers. Russia's share of India's oil imports surged to an all-time high of 23% in September, from just about 2% before the invasion. Jaishankar said India needed to boost its exports to Russia to balance bilateral trade that is now tilted towards Russia. Reporting by Shivam Patel in New Delhi, Editing by Louise Heavens and Tomasz JanowskiOur Standards: The Thomson Reuters Trust Principles.

☆ Indian pharma industry is 'recession proof': Piramal Chairman
▼ + stars: | 2022-10-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIndian pharma industry is 'recession proof': Piramal ChairmanAjay Piramal, Chairman of the Piramal Group says the stronger U.S. dollar and sustained demand for pharmaceutical products are positive for the company's growth.

Search resuls for: "Indian pharma"

20 mentions found